Corticosteroid Refractory Acute Graft vs Host Disease
1 clinical trials · Condition
◉ Watch Corticosteroid Refractory Acute Graft vs Host Disease
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (NCT02913261) | Novartis Pharmaceuticals | 2017-03-10 |
Track Corticosteroid Refractory Acute Graft vs Host Disease automatically
Every clearance here is in the API, with alerts when new ones post.